"Based on input from an international panel of experts, this book provides first-hand experience of the challenges and opportunities facing the delivery of regenerative medicines to patients. It highlights key issues beyond science and clinical translation, such as finance and business models, intellectual property and regulatory landscapes as well as questions of how regenerative medicines will be evaluated for reimbursement. This book will become a pivotal reference to anyone within the healthcare sector interested in understanding and investing in the delivery of regenerative medicines to the benefit of patients"--Provided by publisher
